ストックスクリーナーアプリを入手
436.74
0.05%
-0.27
前日終値:
$437.01
開ける：
$438.81
24時間の取引高:
52,742
Relative Volume:
0.04
時価総額：
$110.84B
収益：
$11.74B
当期純損益:
$3.68B
株価収益率:
30.78
EPS:
14.1888
ネットキャッシュフロー:
$3.34B
1週間 パフォーマンス:
-5.69%
1か月 パフォーマンス:
+3.70%
6か月 パフォーマンス:
-3.27%
1年 パフォーマンス:
-6.91%
1日の値動き範囲:
$435.52
$441.03
1週間の範囲:
$435.52
$463.70
52週間の値動き範囲:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
VRTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
436.85 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.12 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
895.89 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
412.63 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.37 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
This Week’s CGT News: Vertex’s Gene Therapies Show Promise in Younger Children - The Medicine Maker
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating - marketscreener.com
State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by SVB Wealth LLC - MarketBeat
Daiwa Securities Group Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Best Biotech Stocks To Keep An Eye OnDecember 8th - MarketBeat
Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades' - Benzinga
Vertex Will Seek Regulatory Approval for Casgevy in Younger Sickle Cell, Beta-Thalassemia Patients - Precision Medicine Online
Why Vertex Pharmaceuticals (VRTX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Vertex's Gene Therapy Works In Children With Blood Disorders - Benzinga
Thematics Asset Management Acquires 2,642 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - BioSpace
David And Goliath: How A Parent-Led Buyers’ Club Challenged Cystic Fibrosis Giant Vertex - Citeline News & Insights
VRTX Stock Quote Price and Forecast - CNN
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Marshall Wace LLP Has $52.09 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
California Public Employees Retirement System Has $322.79 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Arrowstreet Capital Limited Partnership Purchases Shares of 61,470 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? - Nasdaq
Vertex Pharmaceuticals (NASDAQ:VRTX) Chairman Jeffrey Leiden Sells 63,781 Shares - MarketBeat
Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Charles Wagner Jr Sells 14,000 Shares - MarketBeat
Best Biotech Stocks To Watch NowDecember 6th - MarketBeat
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the - pharmiweb.com
Vertex presents new data on Casgevy at ASH - The Pharma Letter
Vertex Pharmaceuticals Incorporated Presents New Data on CASGEVY, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - marketscreener.com
Vertex Presents New CASGEVY Data Highlighting Benefits In Children Ages 5-11 - Nasdaq
Vertex CRISPR therapy hits early goal in children with blood disorders - BioPharma Dive
Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - Via TT
Mirabella Financial Services LLP Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Epoch Investment Partners Inc. Sells 20,810 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Purchases 143,084 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: WAGNER CHARLES F JR Sells 14,000 Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharma executive chairman sells $28.6m in stock - Investing.com India
Vertex Pharmaceuticals Insider Sold Shares Worth $2,024,955, According to a Recent SEC Filing - marketscreener.com
VP Tatsis Sells 4,500 ($2M) Of Vertex Pharmaceuticals Inc [VRTX] - TradingView
Vertex Pharmaceuticals EVP Sells Shares Under Trading Plan - TradingView
VRTX Analyst Rating Update: Morgan Stanley Raises Price Target | VRTX Stock News - GuruFocus
Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $564 From $516, Maintains Overweight Rating - marketscreener.com
Can Vertex Pharmaceuticals Incorporated (VX1) stock sustain breakout momentumWeekly Trade Report & Technical Confirmation Trade Alerts - Newser
Why Vertex Pharmaceuticals Incorporated stock appeals to dividend seekers2025 Market Overview & Expert Curated Trade Ideas - Newser
Amundi Has $517.92 Million Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - Finviz
Citi Healthcare In Brief: Launch Trajectories Under Scrutiny - Citeline News & Insights
Is Vertex Pharmaceuticals Incorporated stock resilient to inflationWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates - Yahoo Finance
Harding Loevner Global Equity’s Views on Vertex Pharmaceuticals Incorporated (VRTX) - Insider Monkey
Vertex Pharmaceuticals (NASDAQ:VRTX) Raised to Overweight at Morgan Stanley - MarketBeat
Westerkirk Capital Inc. Acquires New Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.49%
0.32%
大文字化:
|
ボリューム (24 時間):